Attenuation of oxidative damage-associated cognitive decline by Withania somnifera in rat model of streptozotocin-induced cognitive impairment
Oxidative stress is a critical contributing factor to age-related neurodegenerative disorders. Therefore, the inhibition of oxidative damage, responsible for chronic detrimental neurodegeneration, is an important strategy for neuroprotective therapy. Withania somnifera (WS) extract has been reported to have potent antioxidant and free radical quenching properties in various disease conditions. The present study evaluated the hypothesis that WS extract would reduce oxidative stress-associated neurodegeneration after intracerebroventricular injection of streptozotocin (ICV-STZ) in rats. To test this hypothesis, male Wistar rats were pretreated with WS extract at doses of 100, 200, and 300 mg/kg body weight once daily for 3 weeks. On day 22nd, the rats were infused bilaterally with ICV-STZ injection (3 mg/kg body weight) in normal saline while sham group received only saline. Two weeks after the lesioning, STZ-infused rats showed cognitive impairment in the Morris water maze test. The rats were sacrificed after 3 weeks of the lesioning for the estimation of the contents of lipid peroxidation, reduced glutathione, and activities of glutathione reductase, glutathione peroxidase, and catalase. Pretreatment with WS extract attenuated behavioral, biochemical, and histological alterations significantly in dose-dependent manner in the hippocampus and cerebral cortex of ICV-STZ-infused rats. These results suggest that WS affords a beneficial effect on cognitive deficit by ameliorating oxidative damage induced by streptozotocin in a model of cognitive impairment.
KeywordsAntioxidant Cognitive impairment Oxidative stress Streptozotocin Withania somnifera
The authors thank the Department of Ayurveda, Yoga and Naturopathy, Unani, Siddha, and Homoeopathy (AYUSH), Ministry of Health and Family Welfare, Government of India, New Delhi, for the financial assistance. The technical assistance of Dharamvir Singh and Abdul Fitr are greatly acknowledged. We greatly acknowledge Dr. Amrish Kumar Tiwari (M.V.Sc. Pathology), Jamia Hamdard, India for the histological interpretation for this manuscript.
Conflict of interest
The authors have no conflict of interest.
- Bhattacharya A, Ghosal S, Bhattacharya SK (2001) Anti-oxidant effect of Withania somnifera glycowithanolides in chronic footshock stress-induced perturbations of oxidative free radical scavenging enzymes and lipid peroxidation in rat frontal cortex and striatum. J Ethnopharmacol 74:1–6Google Scholar
- Claiborne A (1985) Catalase activity. In: Green Wald RA (ed) CRC hand book of methods for oxygen radical research. CRC Press, Boca Raton, pp 283–284Google Scholar
- Davis L, Kuttan G (2001) Effect of Withania somnifera on DMBA induced carcinogenesis. J Ethnopharmacol 75:165–8Google Scholar
- Hoyer S, Nitsch R, Oesterreich K (1991) Predominant abnormality in cerebral glucose utilization in late-onset dementia of the Alzheimer type: a cross-sectional comparison against advanced late-onset and incipient early-onset cases. J Neural Transm Park Dis Dement Sect 31:1–14Google Scholar
- Javed H, Khan MM, Khan A, Vaibhav K, Khan A, Khuwaja G, Ahmad ME, Raza SS, Ashafaq M, Tabassum R, Siddiqui MS, El-Agnaf OM, Safhi MM, Islam F (2011) S-allyl cysteine attenuates oxidative stress associated cognitive impairment and neurodegeneration in mouse model of streptozotocin-induced experimental dementia of Alzheimer's type. Brain Res 389:133–142CrossRefGoogle Scholar
- Khan MB, Khan MM, Khan A, Ahmed ME, Ishrat T, Tabassum R, Vaibhav K, Ahmad A, Islam F (2012) Naringenin ameliorates Alzheimer's disease (AD)-type neurodegeneration with cognitive impairment (AD-TNDCI) caused by the intracerebroventricular-streptozotocin in rat model. Neurochem Int 61:1081–1093PubMedCrossRefGoogle Scholar
- Manjunath MJ, Muralidhara (2012) Withania somnifera prophylaxis abrogates Rotenone-induced oxidative impairments and mitochondrial dysfunctions in striatum and cerebellum of mice: relevance to Parkinson's disease. Cent Nerv Syst Agents Med Chem. PMID:23092410Google Scholar
- Meister A (1988) Glutathione metabolism and its selective modification. J Biol Che 263:1708–17205Google Scholar
- Mishra LC, Singh BB, Dagenais S (2000) Scientific basis for the therapeutic uses of Withania somnifera (ashwagandha): a review. Alternat Med 5:334–346Google Scholar
- Paxinos G, Watson C (1986) The rat brain in stereotaxic coordinates, 2nd edn. Change to Academic Press, SydneyGoogle Scholar
- Sehgal N, Gupta A, Valli RK, Joshi SD, Mills JT, Hamel E, Khanna P, Jain SC, Thakur SS, Ravindranath V (2012) Withania somnifera reverses Alzheimer's disease pathology by enhancing low-density lipoprotein receptor-related protein in liver. Proc Natl Acad Sci U S A 109:3510–3515PubMedCrossRefGoogle Scholar
- Sharada AC, Solomon FE, Devi PU, Udupa N, Srinivasan KK (1996) Antitumor and radiosensitizing effects of withaferin A on mouse Ehrlich ascites carcinoma in vivo. Acta Oncol 35:95–100Google Scholar
- Utley HG, Bernheim F, Hockstein P (1967) Effect of sulfhydryl reagent on peroxidation in microsome. Arch Biochem Biophys 260:521–531Google Scholar